Jumat, 29 September 2017

Merck discontinues HCV programmes - PharmaTimes


PharmaTimes

Merck discontinues HCV programmes
PharmaTimes
Merck & Co has announced that it will discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/ uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection.

and more »


from Health - Google News http://ift.tt/2x1ZvKd


EmoticonEmoticon

:)
:(
hihi
:-)
:D
=D
:-d
;(
;-(
@-)
:o
:>)
(o)
:p
:-?
(p)
:-s
8-)
:-t
:-b
b-(
(y)
x-)
(h)